[1] CAI L, ZHU Z. Dihydropyrimidine dehydrogenase (DPD) and its relation with efficacy and toxicity of 5-fluorouracil [J]. Chin Pharm J (中国药学杂志), 2007, 42(19): 1441-1445.
[2] CAI L, ZHU Z. Progress of research on dihydropyrimidine dehydrogenase genetic polymorphism [J]. Chin Pharm J (中国药学杂志), 2008, 43(9): 113-117.
[3] SAIF M W, SYRIGOS K, MEHRA R, et al. Dihydropyrimidine Dehydrogenase Deficiency (DPD) in Gi malignancies: experience of 4-years [J]. Pak J Med Sci Q, 2007, 23(6): 832-839.
[4] MOORE S. Unanticipated toxicity to capecitabine [J]. Oncol Nurs Forum, 2009, 36(2): 149-152.
[5] FDA. Label approved on 01/27/2000 for FLUOROURACIL, ANDA no.40333 [EB/OL]. FDA, 2000 [2010-11-8]. http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40333_Fluorouracil_Prntlbl.pdf.
[6] FDA. Label approved on 10/27/2000 for CARAC, ANDA no.20985 [EB/OL]. FDA, 2000 [2010-11-8]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20985lbl.pdf.
[7] FDA. Label approved on 03/15/2003 for XELODA, ANDA no.20896 [EB/OL]. FDA, 2003 [2010-11-8]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20896slr012_xeloda_lbl.pdf.
[8] FDA. Label approved on 06/15/2005 for XELODA, ANDA no.20896 [EB/OL]. FDA, 2005 [2010-11-8]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020896s016lbl.pdf.
[9] MHRA. Fluorouracil 50 mg·mL-1 Solution for Injection or Infusion - PL 20851/0013. [EB/OL]. MHRA, 2006 [2010-11-8]. http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2025219.pdf.
[10] EMEA. Summary of product characteristics (xeloda) [EB/OL]. EMEA, 2010 [2010-11-8]. http://www.ema.europa.eu/index/indexh1.htm.
[11] MHRA. Public assessment report (Fluorouracil 50mg/ml solution for injection or infusion) [EB/OL]. MHRA, 2009 [2010-11-8]. http://www.mhra.gov.uk/.
[12] ICH Expert Working Group. Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories [EB/OL]. ICH, 2007 [2010-11-8]. http://www.ich.org/LOB/media/MEDIA3383.pdf.
[13] SHASHI A, FRUEH F W, LESKO L J, et al. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective [J]. Biomarkers Med, 2008, 2(3): 305-311.
[14] FDA. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels [EB/OL]. FDA, 2006 [2010-11-8]. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
[15] MERCIER C, CICCOLINI J, DUPUIS C, et al. Prospective phenotypic screening for DPD deficiency in patients upon fluoropyrimidines administration: impact on the reduction of drug-induced toxicities [J]. J Clin Oncol, 2007, 25(18 suppl): 2541.
[16] MERCIER C, YANG C, ROSCA C, et al. Prospective phenotypic screening for DPD deficiency prior to 5-FU administration: decrease in toxicity, not in efficacy [J]. J Clin Oncol, 2008, 26(15 suppl): 14556.
[17] MERCIER C, BRUNET C, YANG C, et al. Pharmacoeconomic study in head and neck cancer patients: Impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs [J]. J Clin Oncol, 2009, 27(suppl 15): 6508-6515.
[18] BOISDRON-CELLE M, REMAUD G, TRAORE S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency [J]. Cancer Lett, 2007, 249(2): 271-282.
[19] CICCOLINI J, GROSS E, DAHAN L, et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope [J]. Clin Colorectal Cancer, 2010, 9(4): 224-228.
[20] KRISTENSEN M H, PEDERSEN P, MEJER J. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients [J]. J Int Med Res, 2010, 38(4):1313-1323.
[21] Netherlands Cancer Institute. Pharmacogenomic and pharmacokinetic safety and cost-saving analysis in patients treated with fluoropyrimidines [EB/OL]. NIM, 2011 [2011-3-2]. http://clinicaltrials.gov/ct2/show/NCT00838370?term=Dihydropyrimidine+Dehydrogenase+Deficiency&rank=6.
[22] M.D. Anderson Cancer Center. Association of dihydropyrimidine dehydrogenase (DPYD) variants with toxicity telated to capecitabine [EB/OL]. NIM, 2011 [2011-3-2]. http://clinicaltrials.gov/ct2/show/NCT00478686?term=Dihydropyrimidine+Dehydrogenase+Deficiency&rank=1.
[23] Netherlands Cancer Institute. Predicting response to capecitabine in women with metastatic breast cancer [EB/OL]. NIM, 2011 [2011-1-2]. http://clinicaltrials.gov/ct2/show/NCT00953537?term=Dihydropyrimidine+Dehydrogenase+Deficiency&rank=3.
[24] CAI L, ZHU Z, WAN X R, et al. Retrospective analysis of the adverse reactions caused by fluoropyrimidine-containting regime in the treatment of gestational trophoblastic disease [J]. Chin J Drug Appl Monit (中国药物应用与监测), 2009, 6(5): 295-299.
[25] CAI L, ZHU Z, WAN X R, et al. Genetic polymorphism analysis of DPYD in the patients with gestational rophoblastic disease [J]. Chin Pharm J (中国药学杂志), 2009, 44(10): 728-733.
[26] CAI L, ZHU Z, WAN X R, et al. Dihydropyrimidine dehydrogenase activity and its relationship with dihydropyrimidine dehydrogenase genetic polymorphism in 130 patients with gestational trophoblastic disease [J]. Chin J Drug Appl Monit (中国药物应用与监测)，2009, 6(6): 329-333.